论文部分内容阅读
目的:研究日本血吸虫(中国大陆株)22.6 kDa 抗原作为血吸虫病疫苗候选分子的潜能,并探讨Sj22.6/Sj26 GST 融合蛋白作为复合疫苗的可能性。方法:用亲和层析法制备Sj22.6/Sj26 GST融合蛋白。将这两种蛋白分别免疫BALB/c小鼠后进行攻击感染试验。结果:Sj22.6 重组蛋白和Sj22.6/Sj26 GST 融合蛋白分别可诱导小鼠产生32.1% (P< 0.005) 和34.9% (P< 0.02)的成虫减虫率, 28.4% (P< 0.02)和45.1% (P< 0.005)的总减卵率。结论:rSj22.6 与Sj22.6/Sj26 GST融合蛋白均有疫苗应用价值
Objective: To study the potential of 22.6 kDa antigen of Schistosoma japonicum (Chinese mainland strain) as a vaccine candidate for schistosomiasis and to explore the possibility of using Sj22.6 / Sj26 GST fusion protein as a composite vaccine. Methods: Sj22.6 / Sj26 GST fusion protein was prepared by affinity chromatography. BALB / c mice were challenged with the two proteins respectively. Results: The Sj22.6 recombinant protein and Sj22.6 / Sj26 GST fusion protein induced the worm reduction rate and the rate of adult worm reduction by 32.1% (P <0.005) and 34.9% (P <0.02), respectively, 28.4% And 45.1% (P <0.005) of the total egg reduction rate. Conclusion: The vaccine application value of rSj22.6 and Sj22.6 / Sj26 GST fusion protein